The page below is a sample from the LabCE course HER2 Testing in Breast Cancer. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about HER2 Testing in Breast Cancer (online CE course) »
How to Subscribe
Histology CE Package$65 Add to cart
Individual course$20 Add to cart

Herceptin® (Trastuzumab) Response

Her2-positive breast cancer patients may not respond to Herceptin® (trastuzumab) for the following reasons:

  • Inaccurate testing, especially by immunohistochemistry (IHC)
  • Inaccurate scoring, especially by IHC
  • Other molecular markers expressed simultaneously, such as Topo IIa and p53
  • Phosphorylation of HER2 itself
  • Other inhibitors in the PI3K pathway, such as PTEN